Skip to content
Institute for Genetic and Biomedical Research (IRGB) Logo
Logo CNR
  • Home
  • About Us
  • People
  • ProgeNIA
  • Projects
  • Summer School
    • General Information
    • previous editions
      • 2018
      • 2017
      • 2016
      • 2015
      • 2013
      • 2012
      • 2011
  • Contacts
  • Home
  • About Us
  • People
  • ProgeNIA
  • Projects
  • Summer School
    • General Information
    • previous editions
      • 2018
      • 2017
      • 2016
      • 2015
      • 2013
      • 2012
      • 2011
  • Contacts
Home/Projects, Sassari/Ho.Re.O.C.
Ho.Re.O.C.Carla Rozzo2024-05-08T09:02:47+00:00

Project Description

Homologous Recombination Ovarian Cancer

Identification of new prognostic and predictive markers of therapeutic response in patients with advanced ovarian cancer by identifying alterations in homologous recombination (HRD) in the Sardinian population.

 

The study is conducted on a cohort of patient from the female population of North Sardinia. Aim of the project is the identification of new prognostic and predictive markers of therapeutic response in patients with advanced ovarian cancer by identifying alterations in homologous recombination (HRD) in the Sardinian population.

The rapid development of innovative technologies has allowed a considerable broadening of knowledge about genetic aspects related to BRCA genes and their role in the homologous recombination (HR) DNA repair mechanism. It is known that genetic and epigenetic events can cause inactivation of other components of the HR pathway, in addition to the BRCA1 and BRCA2 genes, causing a deficit of such repair mechanisms (Homologous Recombination Deficiency, HRD) in sporadic tumors.

Currently one of the main challenges for the future is to define HRD status in patients with ovarian cancer but with BRCAness phenotype.

The status of the DNA repair system, deficient or proficient, influences the therapeutic choice, determining the sensitivity of cancer cells to PARP inhibitors. The understanding of the prognostic and predictive value of HRD in advanced ovarian cancer is not yet so well explored.

The study is based on genomic mutational profiling through Next Generation Sequencing using the OncomineTM Comprehensive Assay Plus panel (Thermofisher Scientific) that allows the sequencing of more than 500 genes implicated in cancer research, providing, on one hand, information about the presence of mutations predisposing to ovarian cancer in the BRCA1 and BRCA2 genes and, on the other, the characterisation of mutations in other 44 genes likely to be involved in HR. The presence of LOH (loss of genomic heterozygosity) of other genes and the identification of the Copy Number Variations allow to establish a robust Genomic Instability prediction algorithm (GIM score) as a new prognostic and predictive marker of response to PARP inhibitors therapy.

The molecular analysis will be conducted on an FFPE archive of 50 cases of ovarian cancer from a female population of North Sardinia. Sardinian population, which, for geographical and historical reasons, has been isolated for long times and, even within different local ethnic groups, is genetically homogenous, is therefore a model that is able to help the definition of genetic factors underlying complex and/or multifactorial diseases such as cancer.

The predictive score of genomic instability will be compared with data obtained from a group of control cases (Validation Cohort) analysed with other NGS platforms.

The project is coordinated by Maria Cristina Sini, C.N.R. – Institute of Genetic and Biomedical Research (IRGB)-Sassari Unit

Partners: Ospital University Health Unit, Sassari

Funding sources:

Fondazione di Sardegna 2023

  • Amministrazione trasparente
  • Bandi di concorso

Contact Info

Cittadella Universitaria di Cagliari
09042 Monserrato (CA)

Phone: +39 0706754543

Fax: +390706754652

Email: segreteria@irgb.cnr.it

Copyright 2017 IRGB CNR | All Rights Reserved
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT
Go to Top